This is a contrast between GTx Inc. (NASDAQ:GTXI) and Genprex Inc. (NASDAQ:GNPX) based on their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GTx Inc.	N/A	0.00	42.28M	-1.87	0.00
Genprex Inc.	N/A	0.00	9.61M	-0.71	0.00

In table 1 we can see GTx Inc. and Genprex Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 represents GTx Inc. (NASDAQ:GTXI) and Genprex Inc. (NASDAQ:GNPX)’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
GTx Inc.	0.00%	-126.4%	-100.3%
Genprex Inc.	0.00%	-163.8%	-144.6%

Liquidity

The current Quick Ratio of GTx Inc. is 4.3 while its Current Ratio is 4.3. Meanwhile, Genprex Inc. has a Current Ratio of 18.9 while its Quick Ratio is 18.9. Genprex Inc. is better positioned to pay off its short-term and long-term debts than GTx Inc.

Analyst Ratings

The next table highlights the shown recommendations and ratings for GTx Inc. and Genprex Inc.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
GTx Inc.	0	1	0	2.00
Genprex Inc.	0	0	0	0.00

GTx Inc. has a consensus target price of $17, and a 1,123.02% upside potential.

Insider and Institutional Ownership

The shares of both GTx Inc. and Genprex Inc. are owned by institutional investors at 22.5% and 14.8% respectively. Insiders owned 17.8% of GTx Inc. shares. On the other hand, insiders owned about 58.39% of Genprex Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
GTx Inc.	-3.85%	-8.26%	-29.58%	-95.1%	-93.57%	28.21%
Genprex Inc.	11.11%	5.26%	20.87%	-38.7%	0%	45.45%

For the past year GTx Inc.’s stock price has smaller growth than Genprex Inc.

Summary

Genprex Inc. beats on 4 of the 7 factors GTx Inc.

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other medical conditions. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, stress urinary incontinence (SUI), and Duchenne muscular dystrophy (DMD); and selective androgen receptor degraders (SARDs) to treat progressive castration-resistant prostate cancer (CRPC). The companyÂ’s lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with advanced androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

Genprex, Inc., a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome. Genprex, Inc. was founded in 2009 and is based in Austin, Texas.